Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis

Diffuse large B cell lymphoma (DLBCL) is a highly heterogenous malignant disease that remains a major clinical challenge as relapsed and refractory disease is difficult to treat. Apoptosis evasion is a major feature of DLBCL. However, while the suppression of intrinsic apoptosis has long been recognized as a lymphoma-promoting event, the role of extrinsic apoptosis has remained poorly defined. Here, we demonstrated at the genetic level that expression of cFLIP, the most crucial, non-redundant inhibitor of extrinsic apoptosis, in B cells is necessary for the development of diffuse large B cell lymphoma (DLBCL) in an autochthonous murine model. Indeed, B cell-specific deletion of Cflar, the gene encoding for cFLIP, prevented lymphomagenesis mediated by oncogenic Myd88 and overexpression of BCL2. In human lymphoma cells, we showed that the absence of cFLIP sensitizes ABC- but not GCB DLBCL subtype cells to TRAIL- or LPS-induced, Caspase-8-mediated apoptosis. Furthermore, we unveiled a cell death-independent role of cFLIP in the suppression of pro-inflammatory cytokines at the transcriptional level, selectively in the ABC subtype.These results indicate that the suppression of intrinsic apoptosis can support lymphomagenesis only if extrinsic apoptosis is properly controlled. Moreover, licensing extrinsic apoptosis via cFLIP deletion can efficiently promote the death of DLBCL cells despite the suppression of the intrinsic pathway. Overall, these data provide the rationale for the development of cFLIP inhibitors for the treatment of ABC DLBCL and possibly other haematological cancers.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-04-23
DOI
https://doi.org/10.1182/blood.2026033320
Primary Topic
Cell death mechanisms and regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis

Justinas Valiulis, Reinhard Büttner, Ruth Flümann, Ron D. Jachimowicz et al.
Blood
Cell death mechanisms and regulation
article

Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis

Justinas Valiulis, Reinhard Büttner, Ruth Flümann, Ron D. Jachimowicz, S. Klein, Jens Löber, Verena Labi, Moritz Reese, Gero Knittel, Nazli Serin, Alessandro Annibaldi, Hamid Kashkar, Julius C. Enßle, Rebecca E. Poss, S. Spoeck, Martin Peifer, Bjoern Chapuy, Deniz Pinar Savcigil, Michael J. Hallek, Phuong‐Hien Nguyen, Sebastian Scheich, Henning Walczak, Kalvin Nugraha, Anna Lutz, Luca D Schreurs, Giulia Gangarossa, H Christian Reinhardt, Santiago Serrano-Saenz, Thomas Oellerich, Kristie Tanavura Bariboloka, Andreas Villunger
article en

Abstract

Diffuse large B cell lymphoma (DLBCL) is a highly heterogenous malignant disease that remains a major clinical challenge as relapsed and refractory disease is difficult to treat. Apoptosis evasion is a major feature of DLBCL. However, while the suppression of intrinsic apoptosis has long been recognized as a lymphoma-promoting event, the role of extrinsic apoptosis has remained poorly defined. Here, we demonstrated at the genetic level that expression of cFLIP, the most crucial, non-redundant inhibitor of extrinsic apoptosis, in B cells is necessary for the development of diffuse large B cell lymphoma (DLBCL) in an autochthonous murine model. Indeed, B cell-specific deletion of Cflar, the gene encoding for cFLIP, prevented lymphomagenesis mediated by oncogenic Myd88 and overexpression of BCL2. In human lymphoma cells, we showed that the absence of cFLIP sensitizes ABC- but not GCB DLBCL subtype cells to TRAIL- or LPS-induced, Caspase-8-mediated apoptosis. Furthermore, we unveiled a cell death-independent role of cFLIP in the suppression of pro-inflammatory cytokines at the transcriptional level, selectively in the ABC subtype.These results indicate that the suppression of intrinsic apoptosis can support lymphomagenesis only if extrinsic apoptosis is properly controlled. Moreover, licensing extrinsic apoptosis via cFLIP deletion can efficiently promote the death of DLBCL cells despite the suppression of the intrinsic pathway. Overall, these data provide the rationale for the development of cFLIP inhibitors for the treatment of ABC DLBCL and possibly other haematological cancers.

Blood
Goethe University Frankfurt (DE), Innsbruck Medical University (AT), University of Cologne (DE), Universität Innsbruck (AT), MSB Medical School Berlin (DE), Essen University Hospital (DE), University Hospital Frankfurt (DE), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), University Hospital Cologne (DE), University of Florence (IT), Charité - Universitätsmedizin Berlin (DE), University of Lausanne (CH)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Jürgen Manchot Stiftung, BeiGene, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Max-Planck-Gesellschaft, José Carreras Leukämie-Stiftung, Deutsche Krebshilfe, Institut National Du Cancer
Good health and well-being
Openalex Percentile: Top 15%
Cell death mechanisms and regulation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.